Sofela, Agbolahan A, Hilton, David A, Ammoun, Sylwia, Baiz, Daniele, Adams, Claire L, Ercolano, Emanuela, Jenkinson, Michael D ORCID: 0000-0003-4587-2139, Kurian, Kathreena M, Teo, Mario, Whitfield, Peter C et al (show 2 more authors)
(2021)
Fibulin-2: A Novel Biomarker for Differentiating Grade II from Grade I Meningiomas.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 22 (2).
E560-.
Abstract
There is an unmet need for the identification of biomarkers to aid in the diagnosis, clinical management, prognosis and follow-up of meningiomas. There is currently no consensus on the optimum management of WHO grade II meningiomas. In this study, we identified the calcium binding extracellular matrix glycoprotein, Fibulin-2, via mass-spectrometry-based proteomics, assessed its expression in grade I and II meningiomas and explored its potential as a grade II biomarker. A total of 87 grade I and 91 grade II different meningioma cells, tissue and plasma samples were used for the various experimental techniques employed to assess Fibulin-2 expression. The tumours were reviewed and classified according to the 2016 edition of the Classification of the Tumours of the central nervous system (CNS). Mass spectrometry proteomic analysis identified Fibulin-2 as a differentially expressed protein between grade I and II meningioma cell cultures. Fibulin-2 levels were further evaluated in meningioma cells using Western blotting and Real-time Quantitative Polymerase Chain Reaction (RT-qPCR); in meningioma tissues via immunohistochemistry and RT-qPCR; and in plasma via Enzyme-Linked Immunosorbent Assay (ELISA). Proteomic analyses (<i>p</i> < 0.05), Western blotting (<i>p</i> < 0.05) and RT-qPCR (<i>p</i> < 0.01) confirmed significantly higher Fibulin-2 (FBLN2) expression levels in grade II meningiomas compared to grade I. Fibulin-2 blood plasma levels were also significantly higher in grade II meningioma patients compared to grade I patients. This study suggests that elevated Fibulin-2 might be a novel grade II meningioma biomarker, when differentiating them from the grade I tumours. The trend of Fibulin-2 expression observed in plasma may serve as a useful non-invasive biomarker.
Item Type: | Article |
---|---|
Uncontrolled Keywords: | meningioma, atypical, benign, biomarker, plasma |
Divisions: | Faculty of Health and Life Sciences Faculty of Health and Life Sciences > Institute of Systems, Molecular and Integrative Biology |
Depositing User: | Symplectic Admin |
Date Deposited: | 08 Jul 2021 09:15 |
Last Modified: | 25 Jan 2024 19:22 |
DOI: | 10.3390/ijms22020560 |
Open Access URL: | https://doi.org/10.3390/ijms22020560 |
Related URLs: | |
URI: | https://livrepository.liverpool.ac.uk/id/eprint/3129271 |